Premium
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Author(s) -
Hicks JK,
Bishop JR,
Sangkuhl K,
Müller DJ,
Ji Y,
Leckband SG,
Leeder JS,
Graham RL,
Chiulli DL,
LLerena A,
Skaar TC,
Scott SA,
Stingl JC,
Klein TE,
Caudle KE,
Gaedigk A
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.147
Subject(s) - fluvoxamine , escitalopram , citalopram , cyp2c19 , paroxetine , pharmacogenetics , sertraline , dosing , medicine , pharmacology , cyp2d6 , fluoxetine , psychiatry , anxiety , serotonin , genotype , antidepressant , biology , biochemistry , receptor , cytochrome p450 , metabolism , gene
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org ).